Latest Biodefense Stories

PRINCETON, N.J., Feb. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary...

PRINCETON, N.J., Dec. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered...

AUSTIN, Texas, Nov. 14, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced Dr. Amy Altman, vice president of Biodefense will present at the Defense Threat Reduction Agency's (DTRA) 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, which takes place November 14-16, 2011 in Las Vegas, Nevada. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) During the conference, Dr. Altman will present "Fully automated xMAP®-based...

MUNICH, Nov. 2, 2011 /PRNewswire/ -- Abbott's PLEX-ID system provides reliable and rapid results for key microbial biothreat agents and should be considered as a first line analytical tool for biodefense, biosecurity and microbial forensics programs, according to research presented at the 13th Medical Biodefense Conference in Munich. The meeting is a global congress for civilian and military researchers covering the latest developments in the diagnosis, therapy and prevention of diseases...

A government advisory board said on Friday that for now, children will not be given an anthrax vaccine. The board said that ethical issues need to be resolved before the vaccine can be tested in children to be sure it is safe. The government has stockpiled the vaccine due to concerns of terrorist using it as a biological weapon. The National Biodefense Science Board said on Friday that a separate review board should look into the ethical issues of doing such tests in children. The...

DTRA is supporting a USAMRIID clinical study to evaluate a vaccine against ricin toxin. Fort Belvoir, VA (Vocus/PRWEB) April 18, 2011 The Defense Threat Reduction Agency (DTRA) is supporting a clinical study now underway by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate a vaccine against ricin toxin. This is a critical milestone for DTRA's Chemical/Biological Technologies Directorate Translational Medicine Science & Technology Division (CBM)...

ANNAPOLIS, Md., Feb. 8, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011. The data were presented by Dr. Elizabeth Leffel, Director of Non-Clinical...

PRINCETON, N.J., Jan. 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures. The technology is the subject of several United States and foreign patent applications...

PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax(TM) for the prevention of ricin intoxication. RiVax(TM) is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals. The US Orphan...

ANNAPOLIS, Md., Jan. 13, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company recently presented new data from its anthrax anti-toxin and recombinant Protective Antigen (rPA) anthrax vaccine programs at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop and the Biomedical Advanced Research and Development...